DK1273292T3 - Optimeret tobramycinformulering til aerosoldannelse - Google Patents

Optimeret tobramycinformulering til aerosoldannelse

Info

Publication number
DK1273292T3
DK1273292T3 DK01116071T DK01116071T DK1273292T3 DK 1273292 T3 DK1273292 T3 DK 1273292T3 DK 01116071 T DK01116071 T DK 01116071T DK 01116071 T DK01116071 T DK 01116071T DK 1273292 T3 DK1273292 T3 DK 1273292T3
Authority
DK
Denmark
Prior art keywords
formulation
optimized
aerosol formation
tobramycin formulation
tobramycin
Prior art date
Application number
DK01116071T
Other languages
Danish (da)
English (en)
Inventor
Chiara Malvolti
Raffaella Garzia
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177921&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1273292(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of DK1273292T3 publication Critical patent/DK1273292T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK01116071T 2001-07-02 2001-07-02 Optimeret tobramycinformulering til aerosoldannelse DK1273292T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01116071A EP1273292B1 (en) 2001-07-02 2001-07-02 Optimised formulation of tobramycin for aerosolization

Publications (1)

Publication Number Publication Date
DK1273292T3 true DK1273292T3 (da) 2004-10-04

Family

ID=8177921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01116071T DK1273292T3 (da) 2001-07-02 2001-07-02 Optimeret tobramycinformulering til aerosoldannelse

Country Status (27)

Country Link
US (5) US6987094B2 (tr)
EP (1) EP1273292B1 (tr)
JP (1) JP4262086B2 (tr)
KR (1) KR100910888B1 (tr)
CN (1) CN1234346C (tr)
AT (1) ATE267591T1 (tr)
AU (1) AU2002319226B2 (tr)
BG (1) BG66328B1 (tr)
BR (1) BRPI0211320B8 (tr)
CA (1) CA2452638C (tr)
CZ (1) CZ299348B6 (tr)
DE (1) DE60103527T2 (tr)
DK (1) DK1273292T3 (tr)
EA (1) EA006068B1 (tr)
EE (1) EE05392B1 (tr)
EG (1) EG24019A (tr)
ES (1) ES2222294T3 (tr)
HK (1) HK1068784A1 (tr)
HU (1) HU230807B1 (tr)
PL (1) PL202598B1 (tr)
PT (1) PT1273292E (tr)
SI (1) SI1273292T1 (tr)
SK (1) SK285806B6 (tr)
TN (1) TNSN03149A1 (tr)
TR (1) TR200401980T4 (tr)
WO (1) WO2003004005A1 (tr)
ZA (1) ZA200400026B (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
PT3536344T (pt) * 2002-03-01 2020-03-26 Chiesi Farm Spa Formulação superfina de formoterol
ATE350024T1 (de) * 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
US8442280B2 (en) * 2004-01-21 2013-05-14 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis of digital radiography softcopy reading
PT2316419E (pt) 2004-05-17 2012-10-22 Gilead Sciences Inc Combinação de fosfomicina/aminoglicósido em aerossol para o tratamento de infeções respiratórias bacterianas
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2006297289B2 (en) * 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
CA2752296C (en) * 2009-02-18 2018-09-11 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
EP2388008A1 (en) 2010-05-14 2011-11-23 Combino Pharm, S.L. Stable, preservative-free, aqueous formulation for the administration by aerosolization comprising tobramycin
MX336260B (es) 2010-07-12 2016-01-13 Xellia Pharmaceuticals Aps Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
US9271993B2 (en) * 2010-09-13 2016-03-01 University Of Zurich Treatment of bacterial infectious diseases
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
DK2670242T3 (da) * 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
EP2567691B1 (en) 2011-09-12 2014-12-24 Meiji Seika Pharma Co., Ltd. Aqueous compositions comprising arbekacin
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
EP3551191A4 (en) * 2016-12-09 2020-09-09 EnBiotix, Inc. POTENTIALIZATION OF AMINOGLYCOSIDE FOR THE TREATMENT OF BACTERIAL PULMONARY INFECTION
CN108014099B (zh) * 2017-12-15 2019-03-01 武汉兴华智慧医药科技有限公司 一种吸入用妥布霉素溶液及其制备方法
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸***疾病的药物组合物及其制备方法
CN113952320B (zh) * 2021-09-18 2022-03-18 健康元药业集团股份有限公司 一种包含妥布霉素吸入溶液的药物组件及其用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
WO1992011236A1 (en) 1990-12-19 1992-07-09 Smithkline Beecham Corporation Aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
KR100229975B1 (ko) 1991-05-21 1999-11-15 스티븐 에프. 웨인스톡 에어로졸 흡입장치
DE59209686D1 (de) 1991-08-29 1999-06-02 Broncho Air Medizintechnik Ag Medizinisches gerät zur inhalation von dosier-aerosolen
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ES2099415T3 (es) 1991-12-18 1997-05-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
DE4230876A1 (de) 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
WO1994013262A1 (en) 1992-12-09 1994-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) 1992-12-11 1992-12-11 Astra Ab Efficient use
WO1994014490A1 (de) 1992-12-23 1994-07-07 Bernhard Hugemann Verfestigter arzneistoffvorrat für die mechanische erzeugung inhalierbarer wirkstoffpartikel
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
EP0689423B1 (en) 1993-03-17 1997-09-17 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
MX9704550A (es) 1994-12-22 1997-10-31 Astra Ab Formulaciones de medicamentos en aerosol.
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
TR199701167T1 (tr) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Albuterol için ölçülmüs doz inhaleri.
SK284448B6 (sk) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
NZ306281A (en) 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate
CA2217954C (en) 1995-04-14 2005-02-15 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
JP2000514085A (ja) 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
ATE301991T1 (de) 1996-12-04 2005-09-15 Link Products Ltd Arzneimittel zusammensetzungen und vorrichtungen zu deren verabreichung
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19847969A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
PT1283036E (pt) 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
SK286694B6 (sk) 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340492A1 (en) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
PT3536344T (pt) 2002-03-01 2020-03-26 Chiesi Farm Spa Formulação superfina de formoterol
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
US20050083693A1 (en) * 2003-10-21 2005-04-21 Timothy Garrett Flag illumination fixture

Also Published As

Publication number Publication date
JP4262086B2 (ja) 2009-05-13
CA2452638A1 (en) 2003-01-16
AU2002319226B2 (en) 2006-07-06
JP2004535454A (ja) 2004-11-25
CN1234346C (zh) 2006-01-04
EG24019A (en) 2008-03-25
CN1529589A (zh) 2004-09-15
US20120184502A1 (en) 2012-07-19
EE200400050A (et) 2004-04-15
TR200401980T4 (tr) 2004-09-21
SK16432003A3 (sk) 2004-06-08
WO2003004005A1 (en) 2003-01-16
US20040186064A1 (en) 2004-09-23
KR100910888B1 (ko) 2009-08-05
HUP0400387A2 (hu) 2004-09-28
BRPI0211320B1 (pt) 2015-08-18
US6987094B2 (en) 2006-01-17
US7696178B2 (en) 2010-04-13
ATE267591T1 (de) 2004-06-15
PT1273292E (pt) 2004-10-29
US20110212912A1 (en) 2011-09-01
HK1068784A1 (en) 2005-05-06
SK285806B6 (sk) 2007-08-02
EP1273292B1 (en) 2004-05-26
DE60103527D1 (de) 2004-07-01
DE60103527T2 (de) 2005-06-16
CZ299348B6 (cs) 2008-06-25
EA006068B1 (ru) 2005-08-25
US20050163722A1 (en) 2005-07-28
US8168598B2 (en) 2012-05-01
SI1273292T1 (en) 2004-12-31
EP1273292A1 (en) 2003-01-08
BRPI0211320B8 (pt) 2021-05-25
KR20040018403A (ko) 2004-03-03
HU230807B1 (hu) 2018-06-28
EE05392B1 (et) 2011-04-15
TNSN03149A1 (en) 2005-12-23
BG66328B1 (bg) 2013-06-28
CA2452638C (en) 2010-10-05
BG108475A (en) 2005-02-28
PL202598B1 (pl) 2009-07-31
ZA200400026B (en) 2005-03-30
US7939502B2 (en) 2011-05-10
EA200301305A1 (ru) 2004-06-24
US20100098642A1 (en) 2010-04-22
PL367139A1 (en) 2005-02-21
CZ20033580A3 (cs) 2004-10-13
BR0211320A (pt) 2004-09-28
ES2222294T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
DK1273292T3 (da) Optimeret tobramycinformulering til aerosoldannelse
HK1126134A1 (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
BR0012750A (pt) Agente de limpeza para superfìcies cerâmicas vìtreas
WO2001089496A3 (en) Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
ATE183080T1 (de) Neue und verbesserte aminoglykosidformulierung als aerosol
MXPA04001763A (es) Descongestionantes en aerosol para el tratamiento de sinusitis.
HK1111883A1 (en) Use of a composition for preventing or treating respiratory infections and acute otitis media in infants
BR0212586B1 (pt) Composição na forma de uma solução aquosa, e, uso da mesma
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
BR0116757A (pt) Método para o tratamento de infecções pulmonares causadas por bactérias gram-negativas e composição para inalação farmaceuticalmente aceitável.
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
WO2003002064A3 (en) Fused pyrimidine dhfr inhibitors as antibacterials
WO2003032985A3 (en) Concomitant oral and topical administration of anti - infective agents
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
MXPA05013328A (es) Preparaciones que contienen por lo menos un hidroformiato.
MY129637A (en) Use of bismuth subgallate in inhibition of production of nitric oxide synthase.
UA27643U (en) Method for treatment of community-acquired pneumonia in children
WO2004032825A3 (en) Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax
AR022262A1 (es) Formula bactericida de amplio espectro en soluciones concentradas y diluidas
RU2006142470A (ru) Стекло
RU2006143384A (ru) Стекло
Cosgrove et al. The Inflammatory Effects Of Hemoglobin Degradation By Pseudomonas Proteases In The CF Lung
WO2002002088A3 (de) Anthelminthika zur verhinderung von parasitären infektionen bei mensch und tier iii